寻找解决方案--中国的下一代肿瘤免疫研究

In Search of Solutions Next Generation Immunooncology Research in China

肿瘤免疫(I-O)目前是投资高度密集的领域,特别是随着第一代靶向程序性死亡蛋白(PD-1/PD-L1)的免疫检查点抑制剂的成功开发,该领域进入了跳跃式发展。基于此,为进一步提高药物的药效和临床疗效,研发者开始寻找其他免疫治疗靶点,即"下一代"I-O药物。从商业上来看,I-O药物的开发一直由大型跨国制药公司主导。中国虽然拥有全球第二大制药市场,但是在开发这类创新药物方面已滞后于西方国家。意识到这一点,目前正在努力改善现状。截至完稿,中国已有7个抗PD-1/PD-L1抗体产品获批上市,其中2个为全球市场引领者--默克公司的可瑞达■(Keytruda■,通用名为帕博利珠单抗)和百时美施贵宝的欧狄沃(Opdivo■,通用名为纳武利尤单抗),其中4个均由中国的公司开发。不止于此,中国的投资项目正在积极布局下一代免疫治疗靶点,包括采用诸如CAR-T等顶尖技术。在本报告中,我们分析了一些具有前瞻性的下一代I-O靶点,特别关注全球视野下中国的研发情况,同时也预测了随着时间的推移中国的I-O市场发展趋势,以及其对全球市场的潜在影响。

Immuno-oncology(I-O)is an area of intense investment,the pace of which has accelerated with successful development of the first immune checkpoint inhibitors-particularly those targeting the programmed death protein(PD-1/PD-L1).With these approved therapies as a foundation,researchers are now focusing on additional immunological targets,so-called"next generation"therapies,to further improve efficacy and outcomes.Commercially,the major multinational pharmaceutical companies have been leading the change in I-O drug development.China,despite boasting the world’s second largest pharmaceutical market,has found itself lagging the West in terms of introducing these innovative new therapies.The region is now committed to remedying this situation and,as of this writing,has approved seven anti-PD-1/PD-L1 therapies within the last year.These approvals include not only the two global market leaders,Merck&Co.’s Keytruda~?(pembrolizumab)and Bristol-Myers Squibb’s Opdivo~?(nivolumab),but also four assets developed by domestic companies.China’s investment doesn’t stop there;ongoing programs are aimed at an array of next generation targets and the employment of cutting-edge approaches such as CAR T-cell therapy.In this report we analyze some of the leading next generation I-O targets and,more specifically,how the research in China compares with the global scene.We also look ahead to consider how China’s I-O market may develop over time and its potential implications for the wider world.